Skip to content

Ruxolitinib for Severe Fever with Thrombocytopenia Syndrome

Ruxolitinib for Severe Fever with Thrombocytopenia Syndrome

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063759
Enrollment
Unknown
Registered
2022-09-16
Start date
2022-09-19
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Fever with Thrombocytopenia Syndrome

Interventions

Group 1 :oral ruxolitinib

Sponsors

Shandong University Qilu Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with SFTS: Diagnostic criteria for confirmed cases: patients with epidemiological history (history of working, living or traveling in hilly, forest or mountain areas during epidemic season, or history of tick bites within 2 weeks prior to onset), fever and other clinical manifestations, and decreased platelet and white blood cells in peripheral blood. PCR detection of novel Bunyavirus nucleic acid in case samples was positive; 2. Clinical score >= 8 points.

Exclusion criteria

Exclusion criteria: 1. Patients under the age of 18 years; 2. Patients who are pregnant or have a positive pregnancy test before the first administration; 3. Patients with a history of allergy to ruxolitinib.

Design outcomes

Primary

MeasureTime frame
Death or not;

Secondary

MeasureTime frame
length of hospital stay in ICU;length of hospital stay;

Countries

China

Contacts

Public ContactSai Wen

Shandong University Qilu Hospital

wensai2020@163.com+86 18560082135

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026